Aurobindo Pharma has reported results for the quarter and year ended March 31, 2012.
The company’s net profit for the fourth quarter ended March 31, 2012 fell 33.70% to Rs 87.91 crore as compared to Rs 132.59 crore for the quarter ended March 31, 2011. However, the total income has increased by 3.51% to Rs 1100.41 crore for the quarter under review from Rs 1063.10 crore for the corresponding quarter of the previous year.
For the year ended March 31, 2012, the company reported a net loss of Rs 42.61 crore as compared to net profit of Rs 593.80 crore for the previous year. However, the company’s total income has increased by 3.74% to Rs 4300.51 crore for the year from Rs 4145.63 crore in the previous year.
On consolidated basis, the Group’s net loss after taxes and minority interest stood at Rs 123.51 crore for the year under review as compared to net profit of Rs 563.45 crore for the period ago. However, its total income has increased by 5.60% to Rs 4652.10 crore for the year ended March 31, 2012 from Rs 4405.36 crore in the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: